APA (7th ed.) Citation

Bahlis, N. J., Siegel, D. S., Schiller, G. J., Samaras, C., Sebag, M., Berdeja, J., . . . Reece, D. (2022). Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: Updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Leukemia & Lymphoma, 63(6), 1407. https://doi.org/10.1080/10428194.2022.2030477

Chicago Style (17th ed.) Citation

Bahlis, Nizar J., et al. "Pomalidomide, Dexamethasone, and Daratumumab Immediately After Lenalidomide-based Treatment in Patients with Multiple Myeloma: Updated Efficacy, Safety, and Health-related Quality of Life Results from the Phase 2 MM-014 Trial." Leukemia & Lymphoma 63, no. 6 (2022): 1407. https://doi.org/10.1080/10428194.2022.2030477.

MLA (9th ed.) Citation

Bahlis, Nizar J., et al. "Pomalidomide, Dexamethasone, and Daratumumab Immediately After Lenalidomide-based Treatment in Patients with Multiple Myeloma: Updated Efficacy, Safety, and Health-related Quality of Life Results from the Phase 2 MM-014 Trial." Leukemia & Lymphoma, vol. 63, no. 6, 2022, p. 1407, https://doi.org/10.1080/10428194.2022.2030477.